RedHill Acquires Commercial Rights to Rebyota and Clenpiq for $12M Upfront
RedHill Biopharma (NASDAQ:RDHL) has acquired exclusive global commercialization rights to Rebyota and U.S. rights to Clenpiq from Ferring Pharmaceuticals in a deal valued with an upfront payment of $12 million, funded by proceeds from the Talicia divestiture. The agreement includes tiered royalties ranging from 5% to 20%, potential sales milestones, and minimum annual purchase commitments for Rebyota through 2029. RedHill will handle commercialization while Ferring continues manufacturing. The acquired products generated combined U.S. net sales of $37.5 million in 2025—$16.9 million from Rebyota and $20.6 million from Clenpiq—with the latter achieving strong results with minimal promotion. RedHill can leverage its existing infrastructure to scale these products without manufacturing costs, but it faces risks related to supply chain control, royalty obligations, and inventory funding requirements. The deal offers growth potential through expanded GI product coverage; however, success depends on sales performance relative to royalties and the company's ability to manage minimum purchase commitments. The upfront cost appears modest compared to 2025 net sales but does not account for future financial liabilities.
Tickers: $RDHL
Topics: commercial rights acquisition licensing agreement pharmaceuticals revenue potential